<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221110056464N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-15</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The difference in full mouth implant placement in one session and multiple visits</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of clinical and serological responses after post full mouth implantation in single visit versus multiple visits</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67743</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Random sampling will be done among the patients referred to the Faculty of Dentistry in Tabriz who are eligible for the study. The randomization method is simple, and its unit is individual. Our tool for randomizing a table of random numbers. Based on this, the type of treatment is marked with codes A (intervention) and B (control) and placed inside the sealed envelopes. The envelopes are placed in a bag and mixed. Then it is randomly selected from the bag, and treatment is given to the patient by observing the code, Blinding description: This study is single-blind, both the patient and the attending physician will know the type of treatment. The evaluating researcher will not know about the type of intervention performed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Dental Implant.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Surgery and implant placement will be done in one session. The flap and the drilling protocol and placement will be done as standard and the healing abutment will be closed as much as possible. The type of implants used will be the same for all people, and the Korean implant of Deo Company is used. All implants will be surgically implanted in the patient's mouth following the principles of infection control and based on the manufacturer's instructions. One day before implant placement and 2 and 7 days after surgery, inflammatory biomarkers, serum WBC and CRP will be measured by blood tests in the medical diagnosis laboratory. 24 hours after the operation, 48 hours, and 7 days after implant placement, the pain level will be measured by a ten-point Visual Analogue Scale (VAS). The rate of wound healing will be evaluated according to the method mentioned in measuring outcomes through three indices of clinical signs of re-epithelialization (CSR), clinical signs of homeostasis (CSH), and clinical signs of inflammation (CSI). Intervention 2: Control group: Surgery and implant placement will be done in two or three sessions. The flap and the drilling and placement protocol will be done as standard and the healing abutment will be closed as much as possible. The type of implants used will be the same in all people, and the Korean implant of Deo Company is used. All implants will be surgically implanted in the patient's mouth following the principles of infection control and based on the manufacturer's instructions. One day before implant placement and 2 and 7 days after surgery, inflammatory biomarkers, serum WBC and CRP will be measured by blood tests in the medical diagnosis laboratory. 24 hours after the operation, 48 hours and 7 days after implant placement, the pain level will be measured by a ten-point Visual Analogue Scale (VAS). The rate of wound healing will be evaluated according to the method mentioned in measuring outcomes through three indices of clinical signs of re-epithelialization (CSR), clinical signs of homeostasis (CSH) and clinical signs of inflammation (CSI).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Atabak Kashefi Mehr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht St., Tabriz.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3344 4598</telephone>
        <email>kashefimehr.perio@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Atabak Kashefi Mehr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht St., Tabriz.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3344 4598</telephone>
        <email>kashefimehr.perio@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who need a full mouth implant
Healthy gum condition</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant and lactating women
Having any systemic diseases such as diabetes
Patients receiving antibiotics in the last six months
Patients receiving corticosteroid drugs
Use of non-steroidal anti-inflammatory drugs for osteoarthritis rheumatism
Addiction to drugs, smoking or alcohol
History of head and neck radiotherapy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z96.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Presence of tooth-root and mandibular implants</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Surgery and implant placement will be done in one session. The flap and the drilling protocol and placement will be done as standard and the healing abutment will be closed as much as possible. The type of implants used will be the same for all people, and the Korean implant of Deo Company is used. All implants will be surgically implanted in the patient's mouth following the principles of infection control and based on the manufacturer's instructions. One day before implant placement and 2 and 7 days after surgery, inflammatory biomarkers, serum WBC and CRP will be measured by blood tests in the medical diagnosis laboratory. 24 hours after the operation, 48 hours, and 7 days after implant placement, the pain level will be measured by a ten-point Visual Analogue Scale (VAS). The rate of wound healing will be evaluated according to the method mentioned in measuring outcomes through three indices of clinical signs of re-epithelialization (CSR), clinical signs of homeostasis (CSH), and clinical signs of inflammation (CSI).</i_keyword>
      <i_keyword>Control group: Surgery and implant placement will be done in two or three sessions. The flap and the drilling and placement protocol will be done as standard and the healing abutment will be closed as much as possible. The type of implants used will be the same in all people, and the Korean implant of Deo Company is used. All implants will be surgically implanted in the patient's mouth following the principles of infection control and based on the manufacturer's instructions. One day before implant placement and 2 and 7 days after surgery, inflammatory biomarkers, serum WBC and CRP will be measured by blood tests in the medical diagnosis laboratory. 24 hours after the operation, 48 hours and 7 days after implant placement, the pain level will be measured by a ten-point Visual Analogue Scale (VAS). The rate of wound healing will be evaluated according to the method mentioned in measuring outcomes through three indices of clinical signs of re-epithelialization (CSR), clinical signs of homeostasis (CSH) and clinical signs of inflammation (CSI).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum CRP and WBC levels. Timepoint: One day before implant placement and 48 hours after surgery and 7 days after surgery. Method of measurement: It will be done through blood tests of patients.</prim_outcome>
      <prim_outcome>The amount of pain. Timepoint: 48 hours after surgery and 7 days after surgery. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Wound healing rate. Timepoint: One week after surgery. Method of measurement: EHS (EARLY WOUND HEALING) evaluation will be done through three indicators: 1. Clinical signs of re-epithelialization (CSR) (score 0: visible distance between cut edges, score 3: contact between cut edges, score 6: Sticky cutting edges) 2. Clinical signs of hemostasis (CSH) (score 0: bleeding at the cut edge, score 1: the presence of fibrin at the cut edge, score 2: absence of fibrin at the cut edge) 3. Clinical signs of inflammation (CSI) (score 0: redness in More than 50% of the cut length and/or clear swelling, score 1: redness in less than 50% of the cut length, score 2: absence of redness during the cut). The sum of the scores of these three parameters will form the EHS score. Therefore, the EHS score for the ideal wound healing will be ten points, and a score of zero will indicate the worst EHS condition. The wound will be ten points. And a score of zero will indicate the worst EHS condition.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-31</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>3rd Floor, Central Building No. 2, Tabriz University of Medical Sciences, Golgasht St.Tabriz. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
